ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 Septiembre 2023 - 6:00AM
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage biopharma company
focused on accelerating the development and delivery of
transformative medicines in immunology, today announced that
Founder and Chief Executive Officer Shao-Lee Lin, MD, PhD will
participate in a moderated fireside chat during the Morgan Stanley
21st Annual Global Healthcare Conference being held September
11-13, 2023 in New York.
Event: Morgan Stanley
21st Annual Global Healthcare
ConferenceDate: Wednesday, September 13thTime: 11:30 am
ET
A live webcast of Dr. Lin’s fireside chat will be available via
the “Events” section of the Company’s website at www.acelyrin.com.
A replay of the webcast will be archived on the website for 30
days.
About ACELYRINACELYRIN, INC. (Nasdaq: SLRN) is
a Los Angeles area-based late-stage clinical biopharma company –
with additional operations in the San Francisco Bay area – focused
on providing patients life-changing new treatment options by
identifying, acquiring, and accelerating the development and
commercialization of transformative medicines.
Forward Looking StatementsSome statements in
this press release are, or may be considered, forward-looking
statements, including statements regarding ACELYRIN’s business
plans, including our plans to initiate additional clinical trials,
as well as the potential future benefits of our product candidates.
While ACELYRIN, INC. considers any projections to be based on
reasonable assumptions, these forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially from those anticipated in such forward-looking
statements.
CONTACTS:
ACELYRIN, INC.Tyler MarciniakVice President of
Investor Relations,Communications and Corporate
Operationsinvestors@acelyrin.commedia@acelyrin.com
ACELYRIN (NASDAQ:SLRN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ACELYRIN (NASDAQ:SLRN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024